Acadia Pharmaceuticals (ACAD) PT Raised to $30 at Morgan Stanley
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $28.24 -0.49%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $30.00 (from $21.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Canaccord Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
- Apollo Hospitals (APLH:IN) PT Raised to INR8,500 at ICICI Securities
- Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
